Tel Aviv University

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft

Hermann Russ

Christoph Seyfried

Gerd Bartoszyk

Frank Weber

Henning Böttcher

Wojciech Danysz

Christopher Graham Raphael Parsons

Ralf M Devant

Maria Devant, Legal Representative

Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of &#x3b2;-amyloid (A&#x3b2;) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.

Methods for the treatment of glaucoma and age-related macular degeneration by a peptide D-TRP-AIB

Methods for the treatment of glaucoma and age-related macular degeneratiion by a peptide D-TRP-AIB

Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of &#x3b2;-amyloid (A&#x3b2;) derivatives, pharmaceutical compositions for effecting such prevention and interval treatment thereof.

Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases

(R)-(&#x2212;)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof is useful for treatment of adverse effects in treating Parkinson's disease.

Use of(R)-(&#x2212;) -2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts

Compounds of formula I in which R has a meaning as indicated in claim, or one of their optical isomers or pharmaceutically acceptable salts, used for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders and/or for the treatment of extrapyramidal symptoms (EPS) induced by neuroleptics. 

Use of substituted aminomethyl chromans

Growing community of inventors

Frankfurt am Main, Germany

Hermann Russ